Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects
Authors:
- Muhammad Luqman NordinMNMuhammad Luqman Nordin
- Ahmad Khusairi AzemiAhmad Khusairi Azemi
- Abu Hassan NordinANAbu Hassan Nordin
- Walid NabganWNWalid Nabgan
- Pei Yuen NgPNPei Yuen Ng
- Khatijah YusoffKYKhatijah Yusoff
- Nadiah AbuNANadiah Abu
- Kue Peng LimKLKue Peng Lim
- Zainul Amiruddin ZakariaZZZainul Amiruddin Zakaria
- Noraznawati IsmailNINoraznawati Ismail
- Fazren AzmiFAFazren Azmi
Open Access
- 25 June 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (7) , 923
Abstract
Breast cancer is considered the second-leading cancer after lung cancer and is the most prevalent cancer among women globally. Currently, cancer immunotherapy via vaccine has gained great attention due to specific and targeted immune cell activity that creates a potent immune response, thus providing long-lasting protection against the disease. Despite peptides being very susceptible to enzymatic degradation and poor immunogenicity, they can be easily customized with selected epitopes to induce a specific immune response and particulate with carriers to improve their delivery and thus overcome their weaknesses. With advances in nanotechnology, the peptide-based vaccine could incorporate other components, thereby modulating the immune system response against breast cancer. Considering that peptide-based vaccines seem to show remarkably promising outcomes against cancer, this review focuses on and provides a specific view of peptide-based vaccines used against breast cancer. Here, we discuss the benefits associated with a peptide-based vaccine, which can be a mainstay in the prevention and recurrence of breast cancer. Additionally, we also report the results of recent trials as well as plausible prospects for nanotechnology against breast cancer.Keywords
Funding Information
- Fundamental Research Grant Scheme (FRGS) (FRGS/1/2019/SKK06/UKM/02/5)
This publication has 186 references indexed in Scilit:
- Peptide Vaccine Therapy in Colorectal CancerVaccines, 2012
- Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parametersCancer Immunology, Immunotherapy, 2012
- Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccineProceedings of the National Academy of Sciences of the United States of America, 2011
- The Present and Future of Peptide Vaccines for CancerThe Cancer Journal, 2011
- Anti-HER2 vaccines: new prospects for breast cancer therapyCancer Immunology, Immunotherapy, 2010
- Targeting of drugs and nanoparticles to tumorsJournal of Cell Biology, 2010
- Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapiesVaccine, 2009
- Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1Annals of Oncology, 2006
- Expression of a newly defined tumor‐rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I‐restricted cytotoxic T lymphocytes by SART3‐derived peptidesJournal of Orthopaedic Research, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987